Merck & Co., Inc. (NYSE:MRK - Get Free Report) EVP Richard Deluca sold 58,185 shares of Merck & Co., Inc. stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $148.01, for a total value of $8,611,961.85. Following the completion of the sale, the executive vice president owned 112,955 shares of the company's stock, valued at $16,718,469.55. The trade was a 34.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Merck & Co., Inc. Price Performance
Shares of NYSE:MRK opened at $144.49 on Tuesday. Merck & Co., Inc. has a fifty-two week low of $92.11 and a fifty-two week high of $156.92. The business has a 50-day simple moving average of $146.04 and a two-hundred day simple moving average of $128.80. The company has a debt-to-equity ratio of 1.11, a quick ratio of 1.14 and a current ratio of 1.35. The firm has a market cap of $356.20 billion, a price-to-earnings ratio of 148.96, a price-to-earnings-growth ratio of 6.74 and a beta of 0.13.
Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. The firm had revenue of $18.09 billion for the quarter, compared to the consensus estimate of $17.33 billion. During the same quarter last year, the firm posted $2.58 EPS. The business's quarterly revenue was up 4.7% compared to the same quarter last year. On average, analysts expect that Merck & Co., Inc. will post 2.82 earnings per share for the current year.
Hedge Funds Weigh In On Merck & Co., Inc.
Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. grew its holdings in Merck & Co., Inc. by 0.5% during the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company's stock valued at $29,169,479,000 after purchasing an additional 1,073,507 shares during the period. State Street Corp increased its position in Merck & Co., Inc. by 0.8% in the third quarter. State Street Corp now owns 121,422,392 shares of the company's stock worth $17,745,131,000 after buying an additional 1,009,136 shares in the last quarter. Wellington Management Group LLP increased its position in Merck & Co., Inc. by 2.3% in the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company's stock worth $11,083,033,000 after buying an additional 1,934,312 shares in the last quarter. Fisher Asset Management LLC increased its position in Merck & Co., Inc. by 8.3% in the third quarter. Fisher Asset Management LLC now owns 41,699,432 shares of the company's stock worth $6,059,345,000 after buying an additional 3,183,169 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in shares of Merck & Co., Inc. by 10.5% in the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company's stock worth $3,701,831,000 after buying an additional 2,919,780 shares during the period. 76.07% of the stock is owned by institutional investors.
Analyst Ratings Changes
Several equities research analysts recently issued reports on MRK shares. Weiss Ratings upgraded shares of Merck & Co., Inc. from a "hold (c-)" rating to a "hold (c)" rating in a report on Tuesday, August 25th. Leerink Partners lifted their target price on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the stock an "outperform" rating in a research report on Wednesday, September 9th. JPMorgan Chase & Co. boosted their target price on shares of Merck & Co., Inc. from $165.00 to $175.00 and gave the company an "overweight" rating in a research note on Friday, October 30th. Freedom Broker boosted their target price on shares of Merck & Co., Inc. from $125.00 to $140.00 and gave the company a "hold" rating in a research note on Monday, November 2nd. Finally, The Goldman Sachs Group increased their price target on Merck & Co., Inc. from $140.00 to $160.00 and gave the company a "buy" rating in a report on Friday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $155.74.
Check Out Our Latest Stock Report on Merck & Co., Inc.
Merck & Co., Inc. Company Profile
(
Get Free Report)
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company's research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].